TAS 5315

Drug Profile

TAS 5315

Alternative Names: TAS5315

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Mar 2017 3229558 - QC incoporated
  • 11 Nov 2016 Preclinical trials in Systemic lupus erythematosus and Rheumatoid arthritis in Japan (PO)
  • 11 Nov 2016 Pharmacodynamics data from preclinical trial in Rheumatoid arthritis and Systemic lupus erythematosus presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top